Other clinical and hematological complications have been associated with ERCC6L2 deficiency, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)26,31; however, the exact molecular mechanism underlying the pathology of ERCC6L2-associated syndrome is not well understood. This evidence concerns the gene ERCC6L2 and Down syndrome.